drugset / Trial / NCT01635777

Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)

NCT01635777

Phase 2 Completed 37 enrolled AB Foundation World Health Organization · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Miltefosine efficacy will be \>85%

Timeline

Start
2007-07
Primary completion
2009-10
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Miltefosine Small molecule 2.5 mg/kg Oral

Indications

No indication recorded.